{"DataElement":{"publicId":"6712192","version":"1","preferredName":"Individual Pharmacokinetic Study Coagulation Factor VIII Standard Half Life One-stage Clotting Factor Assay  ","preferredDefinition":"Individual; a single human being._A study of the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body._The amount of time needed for a material to lose half of its physical, chemical, or biological activity._Coagulation factor VIII (2351 aa, ~267 kDa) is encoded by the human F8 gene. This protein plays a role in the modulation of coagulation factor IX activity and blood coagulation._A document, established by consensus and approved by a recognized body, that provides, for common and repeated use, rules, guidelines or characteristics for activities or their results._The determination of the amount of factor IX present in a sample.","longName":"Indi_Phar_FactorVIII_Stan_Half","context":"PhenX","contextVersion":"1","DataElementConcept":{"publicId":"6712114","version":"1","preferredName":"Individual Pharmacokinetic Study Coagulation Factor VIII Standard Half Life","preferredDefinition":"Individual; a single human being._A study of the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body._The amount of time needed for a material to lose half of its physical, chemical, or biological activity._Coagulation factor VIII (2351 aa, ~267 kDa) is encoded by the human F8 gene. This protein plays a role in the modulation of coagulation factor IX activity and blood coagulation._A document, established by consensus and approved by a recognized body, that provides, for common and repeated use, rules, guidelines or characteristics for activities or their results.","longName":"Indi_Phar_FactorVIII_Stan_Half","context":"PhenX","contextVersion":"1","ObjectClass":{"publicId":"6706625","version":"1","preferredName":"Individual Pharmacokinetic Study","preferredDefinition":"Individual; a single human being.:A study of the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body.","longName":"C0237401:C49663","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Individual","conceptCode":"C0237401","definition":"Individual; a single human being.","evsSource":"UMLS_CUI","primaryIndicator":"No","displayOrder":"1"},{"longName":"Pharmacokinetic Study","conceptCode":"C49663","definition":"A study of the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"871621AB-70A8-1BF3-E053-F662850AB237","latestVersionIndicator":"Yes","beginDate":"2019-04-21","endDate":null,"createdBy":"PANH","dateCreated":"2019-04-21","modifiedBy":"ONEDATA","dateModified":"2019-04-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6706645","version":"1","preferredName":"Coagulation Factor VIII Standard Half Life","preferredDefinition":"Coagulation factor VIII (2351 aa, ~267 kDa) is encoded by the human F8 gene. This protein plays a role in the modulation of coagulation factor IX activity and blood coagulation.:A document, established by consensus and approved by a recognized body, that provides, for common and repeated use, rules, guidelines or characteristics for activities or their results.:The amount of time needed for a material to lose half of its physical, chemical, or biological activity.","longName":"C16571:C81893:C70916","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Coagulation Factor VIII","conceptCode":"C16571","definition":"Coagulation factor VIII (2351 aa, ~267 kDa) is encoded by the human F8 gene. This protein plays a role in the modulation of coagulation factor IX activity and blood coagulation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Standard","conceptCode":"C81893","definition":"A document, established by consensus and approved by a recognized body, that provides, for common and repeated use, rules, guidelines or characteristics for activities or their results.","evsSource":"CTCAE_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Half Life","conceptCode":"C70916","definition":"The amount of time needed for a material to lose half of its physical, chemical, or biological activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8715E320-D7EF-1BF9-E053-F662850A970E","latestVersionIndicator":"Yes","beginDate":"2019-04-21","endDate":null,"createdBy":"PANH","dateCreated":"2019-04-21","modifiedBy":"ONEDATA","dateModified":"2019-04-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008557","version":"1","preferredName":"Lab Results","preferredDefinition":"the results of laboratory tests.","longName":"LAB_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2CFBA7D-D009-7227-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"87361ACC-0824-248B-E053-F662850A7052","latestVersionIndicator":"Yes","beginDate":"2019-04-23","endDate":null,"createdBy":"PANH","dateCreated":"2019-04-23","modifiedBy":"PANH","dateModified":"2019-08-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6732888","version":"1","preferredName":"One-Stage Clotting Factor Assay","preferredDefinition":"A clotting factor assay where FVIII?deficient plasma is added to test plasma and the APTT reagent, mixed and incubated for 3?5 min. The mixture is then recalcified, and the coagulation time is recorded and compared to a standard curve.","longName":"6732888v1.0","context":"PhenX","contextVersion":"1","type":"Non-enumerated","dataType":"NUMBER","minLength":null,"maxLength":null,"minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2008557","version":"1","preferredName":"Lab Results","preferredDefinition":"the results of laboratory tests.","longName":"LAB_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2CFBA7D-D009-7227-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6732887","version":"1","preferredName":"One-Stage Clotting Factor Assay","preferredDefinition":"A clotting factor assay where FVIII‐deficient plasma is added to test plasma and the APTT reagent, mixed and incubated for 3–5 min. The mixture is then recalcified, and the coagulation time is recorded and compared to a standard curve.","longName":"C159550","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"One-Stage Clotting Factor Assay","conceptCode":"C159550","definition":"A clotting factor assay where FVIII-deficient plasma is added to test plasma and the APTT reagent, mixed and incubated for 3-5 min. The mixture is then recalcified, and the coagulation time is recorded and compared to a standard curve.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"876F43BC-40A9-5EB3-E053-F662850A4510","latestVersionIndicator":"Yes","beginDate":"2019-04-26","endDate":null,"createdBy":"PANH","dateCreated":"2019-04-26","modifiedBy":"ONEDATA","dateModified":"2019-04-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"876F43BC-40BA-5EB3-E053-F662850A4510","latestVersionIndicator":"Yes","beginDate":"2019-04-26","endDate":null,"createdBy":"PANH","dateCreated":"2019-04-26","modifiedBy":"PANH","dateModified":"2019-08-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2793652","version":"1","longName":"PhenX","context":"PhenX","ClassificationSchemeItems":[{"publicId":"6641385","version":"1","longName":"Hemophilia","context":"PhenX"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Data Element Individual Pharmacokinetic Study Coagulation Factor VIII Standard Half Life One-stage Clotting Factor Assay   does not have Preferred Question Text","type":"Preferred Question Text","description":"Data Element Individual Pharmacokinetic Study Coagulation Factor VIII Standard Half Life One-stage Clotting Factor Assay   does not have Preferred Question Text","url":null,"context":"PhenX"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"87361ACC-0837-248B-E053-F662850A7052","latestVersionIndicator":"Yes","beginDate":"2019-04-23","endDate":null,"createdBy":"PANH","dateCreated":"2019-04-23","modifiedBy":"PANH","dateModified":"2020-06-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}